Modern society depends on research and the advancement of science to achieve health and prosperity for all. It is critical to build on already successful science on certain highly prevalent human disease and to do that we need to discuss the current challenges and issues faced.
This is particularly true about chronic kidney disease (CKD) associated with diabetes, hypertension, and obesity. Indeed, despite the huge advancement in treatment and disease management still large mortality and morbidity is caused by CKD. In the USA, 15% or 1 in 7 people are suffering from CKD as reported in 2022. During the same time, it is reported that CKD affects >10% of the general population worldwide, amounting to >800 million individuals.
Indeed, CKD has emerged as one of the leading causes of mortality worldwide, and it is one of a small number of non-communicable diseases that have shown an increase in associated deaths over the past 2 decades. The high number of affected individuals and the significant adverse impact of CKD should prompt enhanced efforts for better prevention and treatment.
Frontiers recognizes the importance of facilitating debate and discussion amongst the community, and so has organized a series of Research Topics, offering a platform for such discussion to occur.
This Research Topic wishes to foster debate and discussion in the community of Experimental Pharmacology and Drug Discovery with pros and cons on the following topics:
• Innovative approaches to CKD drug discovery, such as structural biology, bioinformatics etc.
• Methods of identifying chemical or natural compounds along with their precise targets for CKD.
• Methods of determining the potential pharmacodynamics, pharmacokinetics, safety, and nontoxic properties of novel CKD drugs.
Alongside opinion or perspective pieces, this Research Topic welcomes original research and review articles on the above themes.
All the manuscripts submitted to the Ethnopharmacology section will need to fully comply with the Four Pillars of Best Practice in Ethnopharmacology (you can freely download the full version
here). We also expect that the MS follow the standards established in the
ConPhyMP statement Front. Pharmacol. 13:953205.Specifically, please note the requirements outlined in Pillar 1 and 2, including:
1a) Traditional context - The traditional context must be described in the introduction and supported with bibliographical primary references (see also Section 3 esp. 3d - traditional medicinal preparations and their assessment). This may be based on modern uses of a plant in general healthcare.
